NCT05630365View on ClinicalTrials.gov

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

NACompletedINTERVENTIONAL
Enrollment

1,129

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
COVID-19Influenza AInfluenza Type B
Interventions
DIAGNOSTIC_TEST

Panbio™

The Panbio™ COVID-19/Flu A\&B Rapid Panel device, hereafter referred to as the Panbio™ Rapid Panel, is a visual lateral flow assay for the rapid immuno-chromatographic qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in mid-turbinate nasal swabs

Trial Locations (1)

37209

UCCT @ Complete Health Partners- Nashville, Nashville

All Listed Sponsors
lead

Abbott Rapid Dx

INDUSTRY